5-diethylamino-pent-3-en-2-one | 136571-69-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-diethylamino-pent-3-en-2-one
• 英文别名: (2-Diaethylamino-aethyliden)-aceton；5-Diaethylamino-pent-3-en-2-on；(E)-5-(diethylamino)pent-3-en-2-one
• CAS: 136571-69-2
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: VOSXRWNJQJWXQD-VOTSOKGWSA-N

物化性质

• 沸点：
  223.0±23.0 °C(Predicted)
• 密度：
  0.886±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-diethylamino-pent-3-en-2-one 在 镍 作用下， 生成 5-二乙氨基-2-戊酮
  参考文献：
  名称：

  Guha; Rao; Verghese, Current Science, 1943, vol. 12, p. 82

  摘要：

  DOI：
• 作为产物：
  描述：

  5-chloro-3-penten-2-one 以 乙醚 为溶剂， 反应 3.0h， 生成 5-diethylamino-pent-3-en-2-one
  参考文献：
  名称：

  Ibragimov, I. I.; Mamedov, E. I.; Ismailov, A. T., Journal of Organic Chemistry USSR (English Translation), 1990, vol. 26, # 11, p. 1981 - 1985

  摘要：

  DOI：

文献信息

• Aminopyridazinone compounds as protein kinase inhibitors
  申请人：Jiangsu Hengrui Medicine Co., Ltd.

  公开号：US10323037B2

  公开（公告）日：2019-06-18

  The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

  本公开提供了一种式（I）化合物及其在人类癌症（包括 B 细胞淋巴瘤）和自身免疫性疾病（如类风湿性关节炎、系统性红斑狼疮和多发性硬化症）治疗中的用途。
• [EN] PYRIMIDO DERIVATIVE AND APPLICATION THEREOF IN MEDICINE<br/>[FR] DÉRIVÉ DE PYRIMIDO ET SON APPLICATION EN MÉDECINE<br/>[ZH] 一种嘧啶并环衍生物及其在医药上的应用
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2021093758A1

  公开（公告）日：2021-05-20

  通式(I)所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、共晶或药学上可接受的盐，所述化合物的中间体和制备方法，以及在制备预防或治疗与KRAS G12C活性或表达量相关疾病的药物中的应用。
• BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER
  申请人：Amgen Inc.

  公开号：EP3558955B1

  公开（公告）日：2021-08-11
• AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：ETERNITY BIOSCIENCE INC.

  公开号：US20170152264A1

  公开（公告）日：2017-06-01

  The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
• QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
  申请人：ARROMAX PHARMATECH CO., LTD.

  公开号：US20170247339A1

  公开（公告）日：2017-08-31

  Disclosed are a quinazoline derivative, a preparation method therefor, and a pharmaceutical composition and an application thereof. The present invention provides a compound represented by general formula I, a stereoisomer thereof and a pharmaceutical acceptable salt or a solvate thereof. The quinazoline derivative of the present invention has a unique chemical structure, is characterized by irreversibly inhibiting EGFR tyrosine kinase, has high biological activity, apparently improves the inhibiting effect on the EGFR tyrosine kinase, has quite strong tumor inhibiting effect on tumor cells and a transplantation tumor pathological model of animal tumors, and has good market developing prospects.